Pros And Cons Of Agomelatine

complexation of agomelatine with HP β-CD to enhance aqueous solubility and then to its mucoadhesive tablet for buccal delivery of agomelatine.

A major hurdle that has prevented the commercialization of many promising poorly soluble drug candidates is dissolution rate-limited bioavailability or permeation rate-limited bioavailability. Buccal route of administration provides better penetration of therapeutic and diagnostic agents, and a reduced risk in comparison to conventional treatments. This leads to greater therapeutic efficacy, provides a more comfortable administration for the patient and allows preventing over dose.

Agomelatine is a new agent with a unique pharmacological action, as it is the first melatonergic antidepressant.